312.6K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.42 per share. | 13 Feb 2025 | 2,227 | 126,625 | - | 1.4 | 3,162 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 10 Feb 2025 | 2,554 | 128,852 | - | 1.4 | 3,499 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.50 per share. | 06 Feb 2025 | 2,787 | 918,952 | - | 1.5 | 4,181 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.50 per share. | 06 Feb 2025 | 1,180 | 131,406 | - | 1.5 | 1,770 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.50 per share. | 06 Feb 2025 | 1,033 | 220,239 | - | 1.5 | 1,550 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 652,086 | 652,086 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 51,060 | 0 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 51,060 | 51,060 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 376,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 376,000 | 376,000 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 172,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 172,500 | 172,500 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 257,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 257,500 | 257,500 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 470,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 470,000 | 470,000 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 825,000 | 825,000 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.34 per share. | 03 Feb 2025 | 3,248 | 784,239 | - | 1.3 | 4,352 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 137,500 | 921,739 | - | 0 | Common Stock | |
| Robert Ang | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 147,294 | 0 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 147,294 | 147,294 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 652,086 | 0 | - | - | Employee Stock Option (right to buy) | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 364,000 | 364,000 | - | - | Employee Stock Option (right to buy) | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.34 per share. | 03 Feb 2025 | 1,353 | 80,086 | - | 1.3 | 1,813 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 52,500 | 132,586 | - | 0 | Common Stock | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 364,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 109,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 109,000 | 109,000 | - | - | Employee Stock Option (right to buy) | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 125,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 315,000 | 315,000 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 315,000 | 315,000 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 95,500 | 95,500 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 107,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 107,500 | 107,500 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.34 per share. | 03 Feb 2025 | 1,163 | 168,772 | - | 1.3 | 1,558 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 52,500 | 221,272 | - | 0 | Common Stock | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 28,800 | 0 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 28,800 | 28,800 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 24,410 | 0 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 24,410 | 24,410 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 70,656 | 0 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 70,656 | 70,656 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 121,323 | 0 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 121,323 | 121,323 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 101,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 101,000 | 101,000 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 76,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 76,000 | 76,000 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 95,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Han Wook Choi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 315,000 | 315,000 | - | - | Employee Stock Option (right to buy) | |
| Han Wook Choi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 52,500 | 52,500 | - | 0 | Common Stock | |
| Erez Kalir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.25 per share. | 27 Dec 2024 | 10,334 | 81,439 | - | 1.3 | 12,918 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 06 Nov 2024 | 2,361 | 787,487 | - | 0.9 | 2,030 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 06 Nov 2024 | 999 | 91,773 | - | 0.9 | 859 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 06 Nov 2024 | 875 | 169,935 | - | 0.9 | 753 | Common Stock |
| Amy Quinlan | Vice President of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 06 Nov 2024 | 206 | 50,312 | - | 0.9 | 177 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 01 Nov 2024 | 2,751 | 789,848 | - | 0.8 | 2,201 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 01 Nov 2024 | 1,146 | 92,772 | - | 0.8 | 917 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 01 Nov 2024 | 986 | 170,810 | - | 0.8 | 789 | Common Stock |
| Amy Quinlan | Vice President of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 01 Nov 2024 | 343 | 50,518 | - | 0.8 | 274 | Common Stock |
| Han Wook Choi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 400,000 | 400,000 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.83 per share. | 03 Sep 2024 | 12,657 | 792,599 | - | 0.8 | 10,505 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.83 per share. | 03 Sep 2024 | 5,576 | 171,796 | - | 0.8 | 4,628 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.87 per share. | 06 Aug 2024 | 2,361 | 805,256 | - | 0.9 | 2,054 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.87 per share. | 06 Aug 2024 | 999 | 93,918 | - | 0.9 | 869 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.87 per share. | 06 Aug 2024 | 876 | 177,372 | - | 0.9 | 762 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.94 per share. | 01 Aug 2024 | 2,751 | 807,617 | - | 0.9 | 2,586 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.94 per share. | 01 Aug 2024 | 1,146 | 94,917 | - | 0.9 | 1,077 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.94 per share. | 01 Aug 2024 | 985 | 178,248 | - | 0.9 | 926 | Common Stock |
| Amy Quinlan | Vice President of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.94 per share. | 01 Aug 2024 | 343 | 55,469 | - | 0.9 | 322 | Common Stock |
| Amy Quinlan | Vice President of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.87 per share. | 01 Aug 2024 | 206 | 55,263 | - | 0.9 | 179 | Common Stock |
| Amy Quinlan | Vice President of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.83 per share. | 01 Aug 2024 | 4,402 | 50,861 | - | 0.8 | 3,654 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 03 Jun 2024 | 14,645 | 96,063 | - | 1.4 | 20,357 | Common Stock |
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Sven Ante Lundberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Joshua Resnick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.75 per share. | 06 May 2024 | 2,361 | 810,368 | - | 1.8 | 4,132 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.75 per share. | 06 May 2024 | 999 | 110,708 | - | 1.7 | 1,748 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.75 per share. | 06 May 2024 | 875 | 179,233 | - | 1.7 | 1,531 | Common Stock |
| Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.75 per share. | 06 May 2024 | 834 | 189,403 | - | 1.8 | 1,460 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 01 May 2024 | 2,751 | 812,729 | - | 1.8 | 4,869 | Common Stock |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 01 May 2024 | 1,146 | 111,707 | - | 1.8 | 2,028 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 01 May 2024 | 985 | 180,108 | - | 1.8 | 1,743 | Common Stock |
| Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 01 May 2024 | 917 | 190,237 | - | 1.8 | 1,623 | Common Stock |
| Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.27 per share. | 01 Mar 2024 | 12,657 | 815,480 | - | 2.3 | 28,731 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.27 per share. | 01 Mar 2024 | 5,576 | 181,093 | - | 2.3 | 12,658 | Common Stock |
| Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.27 per share. | 01 Mar 2024 | 6,310 | 191,154 | - | 2.3 | 14,324 | Common Stock |
| Tirtha Chakraborty | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.32 per share. | 06 Feb 2024 | 1,033 | 186,669 | - | 2.3 | 2,397 | Common Stock |
| Attar C. Eyal | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.32 per share. | 06 Feb 2024 | 1,180 | 112,853 | - | 2.3 | 2,738 | Common Stock |
| Robert Ang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.32 per share. | 06 Feb 2024 | 2,788 | 828,137 | - | 2.3 | 6,468 | Common Stock |
| Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.32 per share. | 06 Feb 2024 | 985 | 197,464 | - | 2.3 | 2,285 | Common Stock |
| Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 470,000 | 470,000 | - | - | Employee Stock Option (right to buy) | |
| Jorgensen Nathan | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 50,000 | 198,449 | - | 0 | Common Stock | |
| Chakraborty Tirtha | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 107,500 | 107,500 | - | - | Employee Stock Option (right to buy) | |
| C. Eyal Attar | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 150,000 | 830,925 | - | 0 | Common Stock | |
| Chakraborty Tirtha | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 53,750 | 187,702 | - | 0 | Common Stock | |
| Eyal Attar C. | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 62,500 | 114,033 | - | 0 | Common Stock | |
| Robert Ang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.67 per share. | 07 Aug 2023 | 2,361 | 695,943 | - | 2.7 | 6,304 | Common Stock |
| Eyal C. Attar | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.67 per share. | 07 Aug 2023 | 999 | 52,532 | - | 2.7 | 2,667 | Common Stock |
| Tirtha Chakraborty | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.67 per share. | 07 Aug 2023 | 875 | 140,404 | - | 2.7 | 2,336 | Common Stock |
| Nathan Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.67 per share. | 07 Aug 2023 | 834 | 152,791 | - | 2.7 | 2,227 | Common Stock |
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Sven Ante Lundberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Joshua Resnick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Robert Ang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.14 per share. | 08 May 2023 | 2,361 | 698,304 | - | 4.1 | 9,775 | Common Stock |
| Eyal C. Attar | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.14 per share. | 08 May 2023 | 969 | 53,531 | - | 4.1 | 4,012 | Common Stock |
| Tirtha Chakraborty | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.14 per share. | 08 May 2023 | 875 | 141,279 | - | 4.1 | 3,623 | Common Stock |
| Nathan Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.14 per share. | 08 May 2023 | 834 | 153,625 | - | 4.1 | 3,453 | Common Stock |
| Robert Ang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 01 Mar 2023 | 12,657 | 700,665 | - | 5.5 | 69,740 | Common Stock |
| Tirtha Chakraborty | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 01 Mar 2023 | 5,576 | 142,154 | - | 5.5 | 30,724 | Common Stock |
| Nathan Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 01 Mar 2023 | 6,310 | 154,459 | - | 5.5 | 34,768 | Common Stock |
| Robert Ang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 257,500 | 257,500 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 128,750 | 713,322 | - | 0 | Common Stock | |
| Eyal C. Attar | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 109,000 | 109,000 | - | - | Employee Stock Option (right to buy) | |
| Eyal C. Attar | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 54,500 | 54,500 | - | 0 | Common Stock | |
| Tirtha Chakraborty | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 95,500 | 95,500 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 47,750 | 147,730 | - | 0 | Common Stock | |
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 91,000 | 91,000 | - | - | Employee Stock Option (right to buy) | |
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 45,500 | 160,769 | - | 0 | Common Stock | |
| Robert Ang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2022 | 172,500 | 172,500 | - | - | Employee Stock Option (right to buy) | |
| Robert Ang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2022 | 172,500 | 584,572 | - | 0 | Common Stock | |
| Tirtha Chakraborty | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 76,000 | 96,980 | - | 0 | Common Stock | |
| Tirtha Chakraborty | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 76,000 | 76,000 | - | - | Employee Stock Option (right to buy) | |
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 86,000 | 86,000 | - | - | Employee Stock Option (right to buy) | |
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 86,000 | 115,269 | - | 0 | Common Stock | |
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| Kush M. Parmar | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| Sven Ante Lundberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| Joshua Resnick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| Robert Ang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 376,000 | 376,000 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 101,000 | 101,000 | - | - | Employee Stock Option (right to buy) | |
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Christopher Slapak | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 116,000 | 116,000 | - | - | Employee Stock Option (right to buy) | |
| Kush M. Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 15.30 per share. | 16 Nov 2021 | 238,870 | 4,595,089 | - | 15.3 | 3,654,711 | Common Stock |
| Kush M. Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 15.30 per share. | 16 Nov 2021 | 91,836 | 1,766,634 | - | 15.3 | 1,405,091 | Common Stock |
| Tirtha Chakraborty | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 17,446 | 28,800 | - | - | Employee Stock Option (right to buy) | |
| Tirtha Chakraborty | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.36 per share. | 17 Aug 2021 | 17,446 | 20,980 | - | 1.4 | 23,727 | Common Stock |
| Tirtha Chakraborty | Chief Scientific Officer | 09 Feb 2021 | 3,534 | 3,534 | - | - | Common Stock | ||
| Tirtha Chakraborty | Chief Scientific Officer | 09 Feb 2021 | 48,076 | 0 | - | - | Series B Preferred Stock | ||
| Nathan Jorgensen | Chief Financial Officer | 09 Feb 2021 | 3,534 | 29,269 | - | - | Common Stock | ||
| Nathan Jorgensen | Chief Financial Officer | 09 Feb 2021 | 48,076 | 0 | - | - | Series B Preferred Stock | ||
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) | |
| Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) | |
| David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) | |
| Kush M. Parmar | Director, Ten Percent Owner | 05 Feb 2021 | 45,000,000 | 0 | - | - | Series A-2 Preferred Stock | ||
| Kush M. Parmar | Director, Ten Percent Owner | 05 Feb 2021 | 19,230,768 | 0 | - | - | Series B Preferred Stock | ||
| Kush M. Parmar | Director, Ten Percent Owner | 05 Feb 2021 | 19,230,768 | 0 | - | - | Series B Preferred Stock | ||
| Kush M. Parmar | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) | |
| Kush M. Parmar | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 05 Feb 2021 | 444,444 | 1,858,470 | - | 18 | 7,999,992 | Common Stock |
| Kush M. Parmar | Director, Ten Percent Owner | 05 Feb 2021 | 1,414,026 | 1,414,026 | - | - | Common Stock | ||
| Kush M. Parmar | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 05 Feb 2021 | 111,111 | 4,833,959 | - | 18 | 1,999,998 | Common Stock |
| Kush M. Parmar | Director, Ten Percent Owner | 05 Feb 2021 | 1,414,026 | 4,722,848 | - | - | Common Stock | ||
| Kush M. Parmar | Director, Ten Percent Owner | 05 Feb 2021 | 3,308,822 | 3,308,822 | - | - | Common Stock | ||
| Sven Ante Lundberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) | |
| Joshua Resnick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) | |
| Robert Ang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 51,060 | 51,060 | - | - | Employee Stock Option (right to buy) |